DNA and RNA-based vaccines: Principles, progress and prospects

Vaccine

Volumn 18, Issue 9-10, 1999, Pages 765-777

  Leitner, Wolfgang W ^a   Ying, Han ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dendritic cells; Genetic vaccines; Replicase

Indexed keywords

ADJUVANT; ANTIGEN; CYTOKINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; MESSENGER RNA; PLASMID DNA; RECOMBINANT VACCINE;

BONE MARROW; DNA SEQUENCE; DRUG EFFICACY; GENETICS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANIMALS; BONE MARROW CELLS; DNA REPLICATION; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MUSCLES; RNA; VACCINATION; VACCINES, DNA;

EID: 0032747388     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00271-6     Document Type: Review

References (142)

1. Wolff J.A., Malone R.W., Williams P., et al. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
2. Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:1992;152-154.
3. Mor G. Plasmid DNA: a new era in vaccinology. Biochem. Pharmacol. 55:1998;1151-1153.
4. Whalen R.G. DNA vaccines, cyberspace and self-help programs. Intervirology. 39:1996;120-125.
5. Wang B., Godillot A.P., Madaio M.P., Weiner D.B., Williams W.V. Vaccination against pathogenic cells by DNA inoculation. Curr. Top. Microbiol. Immunol. 226:1998;21-35.
6. Mor G., Singla M., Steinberg A.D., Hoffman S.L., Okuda K., Klinman D.M. Do DNA vaccines induce autoimmune disease? Hum. Gene Ther. 8:1997;293-300.
7. Nichols W.W., Ledwith B.J., Manam S.V., Troilo P.J. Potential DNA vaccine integration into host cell genome. Ann. NY Acad. Sci. 772:1995;30-39.
8. Restifo N., Rosenberg S. The development of recombinant and synthetic cancer vaccines. Curr. Opin. Oncol. 11:1999;50-57.
9. Calarota S., Bratt G., Nordlund S., et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 351:1998;1320-1325.
10. Hoffman S.L., Doolan D.L., Sedegah M., et al. Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use. Vaccine. 15:1997;842-845.
11. Wang R., Doolan D.L., Le T., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:1998;476-480.
12. Wahren B. Gene vaccines. Immunotech. 2:1996;77-83.
13. Robinson H.L. Nucleic acid vaccines: an overview. Vaccine. 15:1997;785-787.
14. Mahvi D.M., Burkholder J.K., Turner J., et al. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Hum. Gene Ther. 7:1996;1535-1543.
15. Montgomery D.L., Ulmer J.B., Donnelly J.J., Liu M.A. DNA vaccines. Pharmacol. Therapeut. 74:1997;195-205.
16. Manickan E., Karem K.L., Rouse B.T. DNA vaccines - a modern gimmick or a boon to vaccinology? Crit. Rev. Immunol. 17:1997;139-154.
17. Davis H.L., Demeneix B.A., Quantin B., Coulombe J., Whalen R.G. Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum. Gene Ther. 4:1993;733-740.
18. Hurpin C., Rotarioa C., Bisceglia H., Chevalier M., Tartaglia J., Erdile L. The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine. 16:1998;208-215.
19. Schirmbeck R., Bohm W., Reimann J. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. J. Immunol. 157:1996;3550-3558.
20. Rosenberg S.A., Zhai Y., Yang J.C., et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90:1999;1894-1900.
21. Jiao S., Williams P., Berg R.K., et al. Direct gene transfer into nonhuman primate myofibers in vivo. Hum. Gene Ther. 3:1992;21-33.
22. Raz E., Carson D.A., Parker S.E., et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc. Natl. Acad. Sci. USA. 91:1994;9519-9523.
23. Chen S.C., Jones D.H., Fynan E.F., et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J. Virol. 72:1998;5757-5761.
24. Etchart N., Buckland R., Liu M.A., Wild T.F., Kaiserlian D. Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J. Gen. Virol. 78:1997;1577-1580.
25. Wang B., Dang K., Agadjanyan M.G., et al. Mucosal immunization with a DNA vaccine induces immune responses against HIV-1 at a mucosal site. Vaccine. 15:1997;821-825.
26. Sasaki S., Sumino K., Hamajima K., et al. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J. Virol. 72:1998;4931-4939.
27. Jones D.H., Clegg J.C., Farrar G.H. Oral delivery of micro-encapsulated DNA vaccines. Developments in Biological Standardization. 92:1998;149-155.
28. Cox G.J., Zamb T.J., Babiuk L.A. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J. Virol. 67:1993;5664-5667.
29. Davis H.L., McCluskie M.J., Gerin J.L., Purcell R.H. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl. Acad. Sci. USA. 93:1996;7213-7218.
30. Sasaki S., Tsuji T., Hamajima K., et al. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1. Infect. Immun. 65:1997;3520-3528.
31. Ray N.B., Ewalt L.C., Lodmell D.L. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Arch. Virol. 142:1997;1011-1019.
32. Krieg A.M., Yi A.K., Matson S., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
33. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA. 94:1997;10833-10837.
34. Davis H.L., Michel M.L., Whalen R.G. Use of plasmid DNA for direct gene transfer and immunization. Ann. NY Acad. Sci. 772:1995;21-29.
35. Davis H.L., Whalen R.G., Demeneix B.A. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum. Gene Ther. 4:1993;151-159.
36. Le Borgne S., Mancini M., Le Grand R., et al. In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen. Virology. 240:1998;304-315.
37. Iwasaki A., Stiernholm B.J., Chan A.K., Berinstein N.L., Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 158:1997;4591-4601.
38. Sprent J. Antigen-presenting cells. Professionals and amateurs. Curr. Biol. 5:1995;1095-1097.
39. Torres C.A., Iwasaki A., Barber B.H., Robinson H.L. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J. Immunol. 158:1997;4529-4532.
40. Levitsky H.I. Accessories for naked DNA vaccines. Nat. Biotech. 15:1997;619-620.
41. Spier R.E. International meeting on the nucleic acid vaccines for the prevention of infectious disease and regulating nucleic acid (DNA) vaccines. Natcher Conference Center NIH, Bethesda, MD 5-8 February, 1996. Vaccine. 14:1996;1285-1288.
42. Fu T.M., Ulmer J.B., Caulfield M.J., et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol. Med. 3:1997;362-371.
43. Davis H.L., Millan C.L., Watkins S.C. Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA. Gene Ther. 4:1997;181-188.
44. Doe B., Selby M., Barnett S., Baenziger J., Walker C. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc. Natl. Acad. Sci. USA. 93:1996;8578-8583.
45. Corr M., Lee D.J., Carson D.A., Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med. 184:1996;1555-1560.
46. Iwasaki A., Torres C.A., Ohashi P.S., Robinson H.L., Barber B.H. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol. 159:1997;11-14.
47. Chattergoon M.A., Robinson T.M., Boyer J.D., Weiner D.B. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. J. Immunol. 160:1998;5707-5718.
48. Porgador A., Irvine K.R., Iwasaki A., Barber B.H., Restifo N.P., Germain R.N. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med. 188:1998;1075-1082.
49. Condon C., Watkins S.C., Celluzzi C.M., Thompson K., Falo L.D. Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1996;1122-1128.
50. Bronte V., Carroll M.W., Goletz T.J., et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. USA. 94:1997;3183-3188.
51. Udey M.C. Cadherins and Langerhans cell immunobiology. Clin. Exp. Immunol. 107:1997;6-8.
52. Bos J.D. The skin as an organ of immunity. Clin. Exp. Immunol. 107:1997;3-5.
53. Degano P., Sarphie D.F., Bangham C.R. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine. 16:1998;394-398.
54. Pertmer T.M., Eisenbraun M.D., McCabe D., Prayaga S.K., Fuller D.H., Haynes J.R. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine. 13:1995;1427-1430.
55. Casares S., Inaba K., Brumeanu T.D., Steinman R.M., Bona C.A. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J. Exp. Med. 186:1997;1481-1486.
56. Williams R.S., Johnston S.A., Riedy M., DeVit M.J., McElligott S.G., Sanford J.C. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc. Natl. Acad. Sci. USA. 88:1991;2726-2730.
57. Klinman D.M., Sechler J.M., Conover J., Gu M., Rosenberg A.S. Contribution of cells at the site of DNA vaccination to the generation of antigen-specific immunity and memory. J. Immunol. 160:1998;2388-2392.
58. Krieg A.M., Yi A.K., Schorr J., Davis H.L. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 6:1998;23-27.
59. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623-1631.
60. Roman M., Martin-Orozco E., Goodman J.S., et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:1997;849-854.
61. Barry M.A., Johnston S.A. Biological features of genetic immunization. Vaccine. 15:1997;788-791.
62. Feltquate D.M., Heaney S., Webster R.G., Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158:1997;2278-2284.
63. Leitner W.W., Seguin M.C., Ballou W.R., et al. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J. Immunol. 159:1997;6112-6119.
64. Prayaga S.K., Ford M.J., Haynes J.R. Manipulation of HIV-1 gp120-specific immune responses elicited via gene gun-based DNA immunization. Vaccine. 15:1997;1349-1352.
65. Fuller D.H., Corb M.M., Barnett S., Steimer K., Haynes J.R. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine. 15:1997;924-926.
66. Norman J.A., Hobart P., Manthorpe M., Felgner P., Wheeler C. Development of improved vectors for DNA-based immunization and other gene therapy applications. Vaccine. 15:1997;801-803.
67. Bohm W., Kuhrober A., Paier T., Mertens T., Reimann J., Schirmbeck R. DNA vector constructs that prime hepatitis B surface antigen-specific cytotoxic T lymphocyte and antibody responses in mice after intramuscular injection. J. Immunol. Methods. 193:1996;29-40.
68. Danko I., Williams P., Herweijer H., et al. High expression of naked plasmid DNA in muscles of young rodents. Hum. Mol. Genet. 6:1997;1435-1443.
69. Montgomery D.L., Shiver J.W., Leander K.R., et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol. 12:1993;777-783.
70. Chen Y., Hu D., Eling D.J., Robbins J., Kipps T.J. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res. 58:1998;1965-1971.
71. Ciernik I.F., Berzofsky J.A., Carbone D.P. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 156:1996;2369-2375.
72. Levy J.A. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57:1993;183-289.
73. McCabe B.J., Irvine K.R., Nishimura M.I., et al. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses. Cancer Res. 55:1995;1741-1747.
74. Thomson S.A., Elliott S.L., Sherritt M.A., et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunol. 157:1996;822-826.
75. Thomson S.A., Sherritt M.A., Medveczky J., et al. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J. Immunol. 160:1998;1717-1723.
76. Restifo N.P., Bacik I., Irvine K.R., et al. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154:1995;4414-4422.
77. Minev B.R., McFarland B.J., Spiess P.J., Rosenberg S.A., Restifo N.P. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 54:1994;4155-4161.
78. Kuhrober A., Wild J., Pudollek H.P., Chisari F.V., Reimann J. DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes. Int. Immunol. 9:1997;1203-1212.
79. Wild J., Gruner B., Metzger K., et al. Polyvalent vaccination against hepatitis B surface and core antigen using a dicistronic expression plasmid. Vaccine. 16:1998;353-360.
80. Maecker H.T., Umetsu D.T., DeKruyff R.H., Levy S. DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin. Vaccine. 15:1997;1687-1696.
81. Chow Y.H., Chiang B.L., Lee Y.L., et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J. Immunol. 160:1998;1320-1329.
82. Irvine K.R., Rao J.B., Rosenberg S.A., Restifo N.P. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156:1996;238-245.
83. Mellstedt H., Fagerberg J., Frodin J.E., et al. Augmentation of the immune response with granulocyte-macrophage colony- stimulating factor and other hematopoietic growth factors [In Process Citation]. Curr. Opin. Hematol. 6:1999;169-175.
84. Conry R.M., Widera G., LoBuglio A.F., et al. Selected strategies to augment polynucleotide immunization. Gene Ther. 3:1996;67-74.
85. Lu Y., Xin K.Q., Hamajima K., et al. Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin. Exp. Immunol. 115:1999;335-341.
86. Kim J.J., Nottingham L.K., Sin J.I., et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J. Clin. Invest. 102:1998;1112-1124.
87. Biragyn A., Tani K., Grimm M.C., Weeks S., Kwak L.W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17:1999;253-258.
88. Pechhold K., Patterson N.B., Craighead N., Lee K.P., June C.H., Harlan D.M. Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. J. Immunol. 158:1997;4921-4929.
89. Townsend S.E., Su F.W., Atherton J.M., Allison J.P. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:1994;6477-6483.
90. Chamberlain R.S., Carroll M.W., Bronte V., et al. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res. 56:1996;2832-2836.
91. Lee C.T., Ciernik I.F., Wu S., et al. Increased immunogenicity of tumors bearing mutant p53 and P1A epitopes after transduction of B7-1 via recombinant adenovirus. Cancer Gene Ther. 3:1996;238-244.
92. Horspool J.H., Perrin P.J., Woodcock J.B., et al. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4. J. Immunol. 160:1998;2706-2714.
93. Lanier L.L., O'Fallon S., Somoza C., et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. 154:1995;97-105.
94. Zhang Y.Q., van Neerven R.J., Van Gool S.W., Coorevits L., de Boer M., Ceuppens J.L. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses. Int. Immunol. 9:1997;1095-1102.
95. Sperling A.I., Auger J.A., Ehst B.D., Rulifson I.C., Thompson C.B., Bluestone J.A. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J. Immunol. 157:1996;3909-3917.
96. Kim J.J., Bagarazzi M.L., Trivedi N., et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat. Biotech. 15:1997;641-646.
97. Lipford G.B., Sparwasser T., Bauer M., et al. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 27:1997;3420-3426.
98. Krieg A.M. Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 4:1996;73-76.
99. Sato Y., Roman M., Tighe H., et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:1996;352-354.
100. Witmer-Pack M.D., Olivier W., Valinsky J., Schuler G., Steinman R.M. Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells. J. Exp. Med. 166:1987;1484-1498.
101. Heufler C., Koch F., Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 167:1988;700-705.
102. Leclerc C., Ronco J. New approaches in vaccine development. Immunol. Today. 19:1998;300-302.
103. Li X., Sambhara S., Li C.X., et al. Protection against respiratory syncytial virus infection by DNA immunization. J. Exp. Med. 188:1998;681-688.
104. Schneider J., Gilbert S.C., Blanchard T.J., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:1998;397-402.
105. Sedegah M., Jones T.R., Kaur M., et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA. 95:1998;7648-7653.
106. Irvine K.R., Chamberlain R.S., Shulman E.P., Surman D.R., Rosenberg S.A., Restifo N.P. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer I. 89:1997;1595-1601.
107. Bell A.F., Burns J.B., Fujinami R.S. Measles virus infection of human T cells modulates cytokine generation and IL-2 receptor alpha chain expression. Virology. 232:1997;241-247.
108. Borrow P., Evans C.F., Oldstone M.B. Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J. Virol. 69:1995;1059-1070.
109. Levitskaya J., Sharipo A., Leonchiks A., Ciechanover A., Masucci M.G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA. 94:1997;12616-12621.
110. Levitskaya J., Coram M., Levitsky V., et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 375:1995;685-688.
111. Berglund P., Tubulekas I., Liljestrom P. Alphaviruses as vectors for gene delivery. Trends Biotechnol. 14:1996;130-134.
112. Tubulekas I., Berglund P., Fleeton M., Liljestrom P. Alphavirus expression vectors and their use as recombinant vaccines: a minireview. Gene. 190:1997;191-195.
113. Caley I.J., Betts M.R., Irlbeck D.M., et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71:1997;3031-3038.
114. Rolls M.M., Webster P., Balba N.H., Rose J.K. Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA. Cell. 79:1994;497-506.
115. Zhou X., Berglund P., Rhodes G., Parker S.E., Jondal M., Liljestrom P. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine. 12:1994;1510-1514.
116. Ying H., Zaks T., Wang R.F., et al. Cancer therapy using a self-replicating RNA vaccine. Nat. Med. 5:(7):1999;823-827.
117. Herweijer H., Latendresse J.S., Williams P., et al. A plasmid-based self-amplifying Sindbis virus vector. Hum. Gene Ther. 6:1995;1161-1167.
118. Dubensky T.W. Jr, Driver D.A., Polo J.M., et al. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J. Virol. 70:1996;508-519.
119. Hariharan M.J., Driver D.A., Townsend K., et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J. Virol. 72:1998;950-958.
120. Berglund P., Smerdou C., Fleeton M.N., Tubulekas I., Liljestrom P. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotech. 16:1998;562-565.
121. Matzinger P. An innate sense of danger. Semin. Immunol. 10:1998;399-415.
122. Glasgow G.M., McGee M.M., Sheahan B.J., Atkins G.J. Death mechanisms in cultured cells infected by Semliki Forest virus. J. Gen. Virol. 78:1997;1559-1563.
123. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 392:1998;86-89.
124. Chelbi-Alix M.K., Sripati C.E. Ability of insulin and dsRNA to induce interferon system and Hsp 70 in fibroblast and epithelial cells in relation to their effects on cell growth. Exp. Cell Res. 213:1994;383-390.
125. Wright C.L., Alder-Moore J.P. The adjuvant effects of mycoviral dsRNA and polyinosinic:polycytidylic acid on the murine immune response. Biochem. Biophys. Res. Commun. 131:1985;949-955.
126. Castelli J.C., Hassel B.A., Wood K.A., et al. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J. Exp. Med. 186:1997;967-972.
127. Rivas C., Gil J., Melkova Z., Esteban M., Diaz-Guerra M. Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Virology. 243:1998;406-414.
128. Tanaka N., Sato M., Lamphier M.S., et al. Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes Cells. 3:1998;29-37.
129. Brand S.R., Kobayashi R., Mathews M.B. The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR. J. Biol. Chem. 272:1997;8388-8395.
130. Tan S.L., Gale M.J. Jr, Katze M.G. Double-stranded RNA-independent dimerization of interferon-induced protein kinase PKR and inhibition of dimerization by the cellular P58IPK inhibitor. Mol. Cell. Biol. 18:1998;2431-2443.
131. Ulmer J.B., Sadoff J.C., Liu M.A. DNA vaccines. Curr. Opin. Immunol. 8:1996;531-536.
132. Leclerc C., Deriaud E., Rojas M., Whalen R.G. The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cell. Immunol. 179:1997;97-106.
133. Tighe H., Corr M., Roman M., Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today. 19:1998;89-97.
134. Ulmer J.B., Deck R.R., DeWitt C.M., Friedman A., Donnelly J.J., Liu M.A. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine. 12:1994;1541-1544.
135. Deck R.R., DeWitt C.M., Donnelly J.J., Liu M.A., Ulmer J.B. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine. 15:1997;71-78.
136. Yokoyama M., Hassett D.E., Zhang J., Whitton J.L. DNA immunization can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site. Vaccine. 15:1997;553-560.
137. Davis H.L., Mancini M., Michel M.L., Whalen R.G. DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. Vaccine. 14:1996;910-915.
138. Olsen C.W., McGregor M.W., Dybdahl-Sissoko N., et al. Immunogenicity and efficacy of baculovirus-expressed and DNA-based equine influenza virus hemagglutinin vaccines in mice. Vaccine. 15:1997;1149-1156.
139. Gramzinski R.A., Millan C.L., Obaldia N., Hoffman S.L., Davis H.L. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol. Med. 4:1998;109-118.
140. Choi A.H., Knowlton D.R., McNeal M.M., Ward R.L. Particle bombardment-mediated DNA vaccination with rotavirus VP6 induces high levels of serum rotavirus IgG but fails to protect mice against challenge. Virology. 232:1997;129-138.
141. Lu S., Santoro J.C., Fuller D.H., Haynes J.R., Robinson H.L. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology. 209:1995;147-154.
142. Pertmer T.M., Roberts T.R., Haynes J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J. Virol. 70:1996;6119-6125.